For example, it inhibits the growth and invasion of gemcitabine-resistant non-small-cell lung cancer (GR-NSCLC) cells by inducing the lysosomal degradation of the EGF receptor (EGFR) and downregulating the CIP2A/PP2A/Akt signaling axis [26]. Here, CIP2A is linked to non-small cell lung carcinoma.